Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Neuropharmacology. 2017 Jan 13;116:371–386. doi: 10.1016/j.neuropharm.2017.01.010

Table 2.

5XFAD behavior: 6 month – oral gavage study.

Behavior age (mon.) wildtype – vehicle wildtype - xamoterol 5XFAD - vehicle 5XFAD – xamoterol Statistics
pre-dose Open Field (distance moved, cm) 3.4 6232.6 ± 323.2 6179.9 ± 288.8 5767.4 ± 355.7 7131.3 ± 437.9 one-way ANOVA
NS

pre-dose Y-Maze (% alternation) 3.5 54.6 ± 3.5 **57.4 ± 1.8 *56.1 ± 2.3 55.2 ± 4.4 one sample t-tests versus chance (50%); * p < .05, ** p < .01

Social Discrimination (discrimination ratio) 5.4 0.034 ± 0.152 0.137 ± 0.098 0.270 ± 0.071 0.109 ± 0.132 one-way ANOVA
NS

Open Field (distance moved, cm) 5.5 7458.0 ± 559.5 6434.4 ± 397.7 7319.6 ± 553.9 7875.5 ± 815.0 one-way ANOVA
NS

Y-Maze (% alternation) 5.6 50.7 ± 3.7 56.4 ± 3.2 ***64.3 ± 2.9 53.0 ± 4.2 one sample t-tests versus chance (50%)
*** p < .001

NOR (discrimination ratio) 5.8 0.391 ± 0.091 0.446 ± 0.037 0.278 ± 0.086 0.551 ± 0.039 one-way ANOVA
F(3,36) = 2.794; p = .054; TREND

Morris Water Maze (escape latency; sec) 6.2 two-way ANOVA
 day 1 58.2 ± 0.9 55.5 ± 1.9 57.9 ± 1.2 50.7 ± 3.2 DAY: F(5,31) = 29.31
***p < 0.001
 day 2 49.7 ± 4.4 47.4 ± 3.7 44.9 ± 4.0 45.1 ± 2.7 GROUP: NS
INTERACTION: NS
 day 3 39.0 ± 3.7 44.9 ± 4.0 42.7 ± 4.5 30.3 ± 3.8
 day 4 40.9 ± 7.7 43.1 ± 4.3 41.7 ± 4.9 30.3 ± 4.0
 day 5 27.6 ± 8.1 35.0 ± 4.2 35.0 ± 4.9 30.5 ± 4.1
 day 6 25.9 ± 4.9 28.7 ± 4.6 34.8 ± 5.5 23.1 ± 4.1
MWM - probe trial (target quadrant ratio) 0.99 ± 0.20 1.06 ± 0.13 1.03 ± 0.19 *1.43 ± 0.10 one sample t-tests
* ratio > 1.0; * p < .05